Literature DB >> 2703007

Detection of tumours with nuclear magnetic resonance spectroscopy of plasma.

S Berger1, K H Pflüger, W A Etzel, J Fischer.   

Abstract

A systematic investigation of cancer detection by water-suppressed nuclear magnetic resonance (NMR) of plasma is reported. With additional suppression of lactate, a statistically significant difference between the linewidths of the methylene group signal of patients with untreated cancer (average linewidth 26.9 +/- 3.9 Hz) and normal controls (average linewidth 31.1 +/- 4.9 Hz) has been found. However, overlap was found between these two groups. It is shown that recognition of malignancy could be improved by consideration of the different relations of the linewidths on the content of serum triglycerides and the observation of a shoulder at the high field side of the methylene signal. Preliminary investigations on lipid fractions separated by ultracentrifugation (UC) indicate a connection of the appearance of the high field shoulder and the HDL lipoprotein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703007     DOI: 10.1016/0277-5379(89)90267-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

1.  Nuclear magnetic resonance spectroscopy of plasma to distinguish between malignant and benign diseases causing jaundice and cholestasis.

Authors:  P A Pasanen; R Kauppinen; M J Eskelinen; K P Partanen; P H Pikkarainen; E M Alhava
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

2.  C-13 NMR spectroscopy of plasma reduces interference of hypertriglyceridemia in the H-1 NMR detection of malignancy. Application in patients with breast lesions.

Authors:  E T Fossel; F M Hall; J McDonagh
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

3.  Failure to detect early breast cancer using in vitro nuclear magnetic resonance spectroscopy of plasma.

Authors:  L Holmberg; U Jakobsson; A Berglund; H O Adami
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.